A Quality of Life Study for Patients With Primary or Metastatic Liver Cancer Who Are Treated With Radioembolization (Y90 Microspheres) or Transcatheter Arterial Embolization (TACE)
- Assess the quality of life (QOL) as defined by the presence or absence of physical,
social, emotional, and functional distress in patients with primary or metastatic liver
cancer undergoing treatment with radioembolization or transcatheter arterial
- Compare the time course of QOL measures between treatment groups in patients treated
with these regimens.
- Compare the time course of QOL measures between patient subgroups defined by
pre-treatment quality of life or tumor burden.
OUTLINE: Patients complete FACT-Hep version 4 surveys on quality of life prior to initiation
of embolization, and at 2 weeks and 1 month after completion of embolization.
Observational Model: Cohort, Time Perspective: Prospective
Quality of life of all patients over the course of treatment
Before treatment, 2 weeks post, and 1 month post
Peggy Gilbertsen, RN, BS
Robert H. Lurie Cancer Center
United States: Institutional Review Board
|Robert H. Lurie Comprehensive Cancer Center at Northwestern University||Chicago, Illinois 60611|